Disease site: Head and Neck
Treatment Modality: Radiotherapy
Status: Open to recruitment
COSTAR is a phase III multi-centre randomised controlled trial designed to demonstrate a difference in the proportion of patients suffering sensori-neural hearing loss of at least 10dB in bone conduction at 4000 Hz, as assessed by an audiogram done 12 months post radiotherapy, in patients treated with cochlea-sparing IMRT and conventional radiotherapy.
The work is supported by the NCRI CTrad Group and the NCRI Head and Neck Cancer Studies Group.
Dr Chris Nutting
The Royal Marsden NHS Foundation Trust
Source of funding:
Cancer Research UK